GE Announces Phase 2 Flutemetamol Results

GE GE Healthcare announced today that results from its multicenter phase 2 study of flutemetamol were published in the September issue of Annals of Neurology. Flutemetamol is an investigational positron emission tomography imaging agent being developed by GE Healthcare, in the field of brain imaging. The purpose of the phase 2 study was to investigate the efficacy of flutemetamol in differentiating between patients with clinically probable Alzheimer's disease and cognitively intact healthy volunteers. The primary endpoint was the efficacy of blinded assessments of flutemetamol binding to Beta-amyloid, the major constituent of amyloid plaque, which is a pathological hallmark of AD. In the study, subjects with a high probability of amyloid and a low probability of amyloid underwent PET imaging with flutemetamol. Five independent image readers, each blinded to the subject's clinical status, separately decided if each subject's image corresponded to normal or raised amyloid levels. The accuracy of image assessments was determined by comparing them to the subjects' clinical diagnoses.